2851016-14-1
Chemical Structure
Silodosin Glucuronide-d4
Synonym(s): Silodosin β-D-glucuronide-d4; KMD-3213G-d4
- CAS No.: 2851016-14-1
- Formula:C31H36D4F3N3O10
- Molecular Weight:675.68
InChIKey: ZSZSAUNNNUTBDH-IQOCOFPESA-N
SMILES: O=C([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCCN2CCC3=C2C(C(N)=O)=CC(C[C@H](NC([2H])([2H])C([2H])(OC4=CC=CC=C4OCC(F)(F)F)[2H])C)=C3)O1)O
Biological Activity: Silodosin Glucuronide-d4 (Silodosin β-D-glucuronide-d4; KMD-3213G-d4) is the deuterated-labeled Silodosin Glucuronide (HY-164132). Silodosin Glucuronide (Silodosin β-D-glucuronide; KMD-3213G) is generated in vivo via glucuronidation of the α1A-adrenoceptor antagonist Silodosin (HY-10122). Silodosin Glucuronide is a key biomarker measured simultaneously with the parent drug in human pharmacokinetic/bioequivalence studies of Silodosin formulations[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Silodosin Glucuronide-d4 | Silodosin Glucuronide-d4 (Silodosin β-D-glucuronide-d4; KMD-3213G-d4) is the deuterated-labeled Silodosin Glucuronide (HY-164132). Silodosin Glucuronide (Silodosin β-D-glucuronide; KMD-3213G) is generated in vivo via glucuronidation of the α1A-adrenoceptor antagonist Silodosin (HY-10122). Silodosin Glucuronide is a key biomarker measured simultaneously with the parent drug in human pharmacokinetic/bioequivalence studies of Silodosin formulations. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Silodosin Glucuronide | Silodosin Glucuronide (Silodosin β-D-glucuronide; KMD-3213G) is generated in vivo via glucuronidation of the α1A-adrenoceptor antagonist Silodosin (HY-10122). Silodosin Glucuronide is a key biomarker measured simultaneously with the parent drug in human pharmacokinetic/bioequivalence studies of Silodosin formulations. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shah PA, et al. Determination of silodosin and its active glucuronide metabolite KMD-3213G in human plasma by LC-MS/MS for a bioequivalence study. Biomedical chromatography : BMC. 2018 Feb;32(2).
- [2]. Schilit S, et al. Silodosin: A Selective α1A-Adrenergic Receptor Antagonist for the Treatment of Benign Prostatic Hyperplasia. Clinical Therapeutics. 2009, 31 (11): 2310-2322.
